Navigation Links
Simcere Pharmaceutical Group Announces Interim Results of Endu Phase IV Clinical Study
Date:9/3/2008

of the open-label, large sample, multi-center Endu phase IV clinical study affirms the safety and therapeutic efficacy of Endu acting in conjunction with platinum-based chemotherapy. With our continued research of Endu Phase IV, we will collect more clinical data to further evaluate the safety and efficacy of Endu."

To date, over 2,000 NSCLC patients have been recruited for Endu Phase IV clinical study. The final results of the study will be announced in the first half of 2010.

As a leading patented anti-cancer biotech product in China, Endu is recommended in the National Comprehensive Cancer Network of China Clinical Practice Guidelines in Oncology Chinese Version (2006-2008)as a first line treatment for NSCLC.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endu in the rapidly growing China market. In recent years, Simcere has been focusing its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic stroke management medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. Simcere currently manufactures and sells more than 50 pharmaceutical products including antibiotics, anti-cancer medication and stroke management medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmac
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
2. Panacea Pharmaceuticals Announces Issuance of a U.S. Patent Covering Anti-HAAH Antibodies
3. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
4. Indevus Pharmaceuticals Announces Completion of Enrollment in Phase III Trial of PRO 2000
5. Catalyst Pharmaceutical Partners Announces Publication of Animal Data Demonstrating Vigabatrin Effective for Weight Loss
6. Addrenex Pharmaceuticals New Hires Further Company Goal to Identify New Drugs for Adrenergic Regulation
7. Vion Pharmaceuticals Enters Into Agreement With HOVON to Conduct a Phase III Clinical Trial of Cloretazine(R) in Combination With Frontline AML and MDS Therapy
8. Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome)
9. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
10. Oramed Pharmaceuticals Announces Successful Phase 2A Clinical Trial of its Oral Insulin Capsule
11. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
(Date:1/22/2015)... (NYSE: RMD ) today announced results for its ... $423.0 million, a 10 percent increase compared to the quarter ... constant currency basis). Net income was $91.2 million, an increase ... 2013. Diluted earnings per share for the quarter were $0.64, ...
(Date:1/22/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced that it ... on Tuesday, Jan. 27, 2015, after the close of the U.S. ... with the investment community at 2 p.m. PT. Participating in the ... and chief executive officer, and other members of Amgen,s senior management ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... 6, 2011 The Bupa Health Foundation and ... brain health app, the latest digital tool to help in ... that links brain health and a reduced risk of dementia, ... dementia risk reduction iPhone app designed to help people monitor ...
... Dec. 6, 2011 Texas Instruments Incorporated (TI) (NYSE: ... and MSP430F663x families adding more performance ... portfolio. Developers can immediately take advantage of the microcontrollers, ... high precision measurement and connectivity. The F563x and F663x ...
Cached Medicine Technology:Bupa Health Foundation and Alzheimer's Australia Announce UK Availability of Brain Health App 2Bupa Health Foundation and Alzheimer's Australia Announce UK Availability of Brain Health App 3TI's new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications 2TI's new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications 3
(Date:1/22/2015)... VogueQueen is a seasoned and trusted leader who consistently ... thrilled to have it lead the wedding dress industry into ... prom dresses for the global market. , “The CEO of ... he focuses on continuing the goal of operational excellence and ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... For over 20 years, Dr. David Cruz of ... area has treated just about every type of injury that can ... for those same twenty-plus years, the team at Doctors on ... the best possible doctor. With the combined breadth of ...
(Date:1/22/2015)... (PRWEB) January 23, 2015 Recently, Weddingshe.com has ... catalog, and has announced its highest annual revenues in the ... on its popular glamorous wedding dresses. , According to the ... important wedding dress promotions for them in 2015. This point ...
(Date:1/22/2015)... NY (PRWEB) January 22, 2015 As interest ... overall health care gains momentum worldwide, Rev. Eric J. ... HealthCare Chaplaincy Network (HCCN), will be the keynote speaker ... care in Israel’s public health system. , The conference, “Hope ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... Sanford Rose Associates – Charleston , a leading executive search firm specializing in healthcare information technology has named Bonnie R. Siegel as Associate Partner, leading the ... ... ... ...
... assistant professor of medicine at the Boston University School of ... Health Quality, Outcomes, and Economic Research at the Bedford VA ... Young Investigator prizewinner. Rose received this award for his article ... 1) which appeared in the Journal of Thrombosis and ...
... ... Enterprise-Class Performance, Resilience, and Management. , ... Santa Clara, CA (PRWEB) March 18, 2010 -- ... services across the county, has completed the deployment of Aerohive Networks’ ...
... Strategies ... ... Institute today announced its Inaugural Encouraging Development of Therapeutics for Neglected Diseases ... Philadelphia, PA. This forum is designed to bring together many of the major stakeholders ...
... ... the Reliability Compliance Program for NERC and NPCC standards covering 300 power generators, ... , ... March 18, 2010 -- MetricStream, Inc., the market leader in enterprise Governance, Risk, ...
... good choice for losing weight , THURSDAY, March 18 (HealthDay News) ... health value of a low-fat diet comes to the unexciting conclusion ... an eating regimen had almost no effect on cholesterol levels, according ... American Journal of Clinical Nutrition on the Women,s Health Initiative ...
Cached Medicine News:Health News:Sanford Rose Associates - Charleston Adds Associate Partner 2Health News:Sanford Rose Associates - Charleston Adds Associate Partner 3Health News:BUSM researcher receives prestigious young investigator award 2Health News:NHS Lincolnshire Applies Intuitive ‘Cooperative Control' Wireless LAN 2Health News:NHS Lincolnshire Applies Intuitive ‘Cooperative Control' Wireless LAN 3Health News:Cambridge Healthtech Announces Its Inaugural Encouraging Development of Therapeutics for Neglected Diseases Conference 2Health News:Cambridge Healthtech Announces Its Inaugural Encouraging Development of Therapeutics for Neglected Diseases Conference 3Health News:Cambridge Healthtech Announces Its Inaugural Encouraging Development of Therapeutics for Neglected Diseases Conference 4Health News:IESO, one of the Independent System Operators in North America, Selects MetricStream GRC for Monitoring Compliance to Electric Reliability Standards 2Health News:IESO, one of the Independent System Operators in North America, Selects MetricStream GRC for Monitoring Compliance to Electric Reliability Standards 3Health News:Low-Fat Diet Does Little to Alter Cholesterol Levels 2Health News:Low-Fat Diet Does Little to Alter Cholesterol Levels 3
This ENDOLOOP suture has a suture type - 0 PDSII and a 1.5 inch diameter....
... 18'' long ligature inserted into a plastic tube. The ... on the other. The suture protrudes from the narrow ... a knot which becomes secure after the device is ... to the scored end of the plastic tube. The ...
... The Triage® C. difficile Panel is an ... C. difficile common antigen (glutamate dehydrogenase) and ... test is used as an aid in ... and is part of the Triage Microbiology ...
ELISA for the detection of C. difficile toxin A in stool specimens...
Medicine Products: